All In Biotech

Drug Trial Radar · NCT05069610

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

A Parallel Treatment, Phase 2a, Double-blind, Randomized, Placebo-controlled, 4-arm Study to Evaluate the Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adult Aged 20 to 70 Years With Mild to Moderate COVID-19

Last checked: Nov 19, 2026Latest source record: Dec 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Mar 21, 2022

Primary completion

Oct 31, 2023

Study completion Dec 18, 2023

Sponsor

Lead sponsor
Advagene Biopharma Co. Ltd.Industry
Sponsor type
Industry
First posted
Oct 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

AD17002 has demonstrated superior safety and efficacy as a nasal adjuvant function to an influenza vaccine in two completed clinical studies, and has innate immune modulatory and anti-inflammatory properties which could potentially be an effective treatment for SARS-CoV-2 infection. This Phase 2a, multi-center study is set up to assess the safety, tolerability, and potential efficacy of AD17002 in participants with mild to moderate COVID-19. The Immunogenicity of repeated doses of AD17002 will also be explored.

Conditions

  • COVID-19

Interventions

  • AD17002Biological

    A recombinant protein

  • Placebo (Formulation buffer)Biological

    Formulation buffer

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants who experience adverse eventsTime frame: 7 weeks
  2. The proportion of participants with treatment-emergent adverse events (TEAE) leading to investigational medicinal products (IMPs) discontinuationTime frame: 7 weeks
  3. The nasal tolerability to investigational medicinal products (IMPs)Time frame: 7 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Advagene Biopharma

    Taipei, Taiwan

  • Chang Gun Medical Foundation

    Taoyuan, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.